Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy

Go back to Cabaletta Bio outlines 2026 strategic priorities for autoimmune therapy
(NASDAQ: CABA) Delayed: 3.19 +0.09 (2.90%)
Previous Close $3.10    52 Week High
Open $3.04    52 Week Low
Day High $3.24    P/E N/A 
Day Low $2.95    EPS
Volume 5,738,129